Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 4/20 | 0.64 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7789498 | 1.00 | SRD5A1 (0.64) | SRD5A1PARP1SIGMAR1IDO1PDPK1 | |
| SCHEMBL698225 | 1.00 | SRD5A1 (0.64) | SRD5A1PARP1SIGMAR1IDO1PDPK1 | |
| SCHEMBL7797739 | 1.00 | SRD5A1 (0.64) | SRD5A1PARP1SIGMAR1IDO1PDPK1 | |
| SCHEMBL9964019 | 0.88 | SRD5A1 (0.54) | SRD5A1PARP1RAB9A | |
| SCHEMBL1952744 | 0.88 | SRD5A1 (0.54) | SRD5A1PARP1RAB9A | |
| SCHEMBL1952747 | 0.88 | SRD5A1 (0.54) | SRD5A1PARP1RAB9A | |
| SCHEMBL1207971 | 0.88 | SRD5A1 (0.54) | SRD5A1PARP1RAB9A | |
| SCHEMBL21357347 | 0.87 | SRD5A1 (0.49) | SRD5A1PARP1SIGMAR1IDO1PDPK1 | |
| SCHEMBL7797837 | 0.78 | SRD5A1 (1.00) | SRD5A1NPY5R | |
| SCHEMBL7796251 | 0.78 | SRD5A1 (0.70) | SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0591583-B1 | Benzo (f) quinolinones as 5-alpha-reductase inhibitors | LILLY CO ELI (US) | 2001-12-19 | — | — | EP | claimed |
| EP-0532190-B1 | Benzo(f)quinolinones as 5-alpha-reductase inhibitors | LILLY CO ELI (US) | 2000-12-27 | — | — | EP | claimed |
| WO-1996035422-A1 | METHODS FOR INHIBITING BONE LOSS | ELI LILLY AND COMPANY (US) | 1996-11-14 | — | — | WO | claimed |
| EP-0591583-A1 | Benzo (f) quinolinones as 5-alpha-reductase inhibitors | ELI LILLY AND COMPANY (US) | 1994-04-13 | — | — | EP | claimed |
| US-5239075-A | PROCESS FOR THE PREPARATION OF BENZO (F) QUINOLINONES | ELI LILLY AND COMPANY (US) | 1993-08-24 | — | — | US | claimed |
| EP-0532190-A2 | Benzo f quinolinones as 5-alpha-reductase inhibitors | ELI LILLY AND COMPANY (US) | 1993-03-17 | — | — | EP | claimed |
| EP-2693875-A2 | BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE | British Columbia Cancer Agency Branch (CA) | 2014-02-12 | — | — | EP | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| WO-2012139039-A2 | BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2012-10-11 | — | — | WO | disclosed |
| EP-2423207-A2 | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-2001863-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007119463-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-25 | — | — | WO | disclosed |
| WO-1996009046-A1 | 5α-REDUCTASE INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
| US-5495021-A | STEROID 5 ALPHA-REDUCTASE INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-27 | — | — | US | disclosed |
| WO-1995005821-A1 | DI- AND TETRA-HYDROBENZO[F]QUINOLIN-3-ONES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-03-02 | — | — | WO | disclosed |
| US-5334767-A | Steroid 5a-reductase inhibitor | ELI LILLY AND COMPANY (US) | 1994-08-02 | — | — | US | disclosed |
| EP-0591583-A1 | Benzo (f) quinolinones as 5-alpha-reductase inhibitors | ELI LILLY AND COMPANY (US) | 1994-04-13 | — | — | EP | disclosed |
| US-5239075-A | PROCESS FOR THE PREPARATION OF BENZO (F) QUINOLINONES | ELI LILLY AND COMPANY (US) | 1993-08-24 | — | — | US | disclosed |
| EP-0532190-A2 | Benzo f quinolinones as 5-alpha-reductase inhibitors | ELI LILLY AND COMPANY (US) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MAPT, PRMT1, PSEN1 | SRD5A1 2464/4885PARP1 1074/4885SIGMAR1 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.